The Company’s notes receivable, net consists of investments in loans to buyers of charged-off and nonperforming receivable portfolios through HGC and financing of laboratory equipment sales through ALT. As of June 30, 2024 and December 31, 2023, the Company’s outstanding notes receivables related to loans to buyers of charged-off and nonperforming receivable portfolios, net of unamortized deferred fees and costs on originated loans, and adjusted for the reserve for credit losses was $13.4 million and $17.5 million, respectively. The activity during the six months ended June 30, 2024 includes the additional investment in notes receivable of approximately $4.3 million, which was offset by principal payments made by borrowers of approximately $6.1 million and noncash transfer of notes receivable to equity method investments of approximately $2.5 million.

As of June 30, 2024, the Company’s outstanding notes receivables related to financing of laboratory equipment sales, net of unamortized deferred fees and costs on originated loans and adjusted for the reserve for credit losses was $0.2 million. There was no notes receivable balance related to financing of laboratory equipment sales as of December 31, 2023. The activity during the six months ended June 30, 2024 includes the investment in notes receivable of approximately $0.2 million, which was offset by immaterial principal payments made by purchasers, deferred financing fees, and allowance for credit losses.

The table below shows the Company’s lending activity as of June 30, 2024 (in thousands):



	June 30, 2024
Notes receivable as of December 31, 2023	$	18,262
Investment in notes receivable		4,516
Noncash transfer of notes receivable to equity method investments		(2,487	)
Principal repayments		(6,132	)
Notes receivable, as of June 30, 2024		14,159
Deferred financing fees and costs, net		(95	)
Allowance for credit loss		(466	)
Notes receivable, net, June 30, 2024	$	13,598

In accordance with ASC 326, the Company performs a review of notes receivable on a quarterly basis. During the six months ended June 30, 2024, the Company recorded a credit of $0.2 million to the provision for credit losses in selling, general and administrative expense on the consolidated statement of income, due to the decrease in balance of notes receivables. As of June 30, 2024 and December 31, 2023, the allowance for credit losses was approximately $0.5 million and $0.7 million, respectively. As of June 30, 2024, the amortized cost basis of notes receivable in nonaccrual status was $5.7 million.